Mixing different subscriptions within a cluster is not permitted. For example, if a cluster contains 5 nodes, all 5 nodes must be DataStaxĮnterprise. Requirement for Uniform LicensingĪll nodes in each DataStax Licensed cluster must be uniformly licensed to use the same Other platforms or versions may work, but have not been tested. The following platforms and versions are supported and tested by DataStax to work withĭataStax products. Supports an OS or JVM after standard support has ended. Recommendations and best practices from the DataStax field team.ĭataStax documentation for open-source Apache Cassandra® 2.1, 2.2, 3.0, and 3.x DataStax Distribution of Apache Cassandra 3.11 and Cassandra documentation included with DataStax Enterprise.ĭataStax provides production ready Docker images for DataStax Enterprise (DSE), DSE OpsCenter, and DataStax Studio.ĭescribes helpful features and icons used in DataStax documentation.Īttention: Be sure to check the support status for your platform. Tools for developing and managing your database.
#Ami 2016.09 libjansson install#
#Ami 2016.09 libjansson software#
Third-party software licensed by DataStax, Inc. The following links provide access to DataStax API documentation.Ĭompatibility between different product versions and support status. Supported operating systems, JRE/JDKs, and browsers for DataStax Enterprise, DataStax Studio, and DSE OpsCenter. Published by Elsevier Ltd.Documentation for installing, configuring, upgrading, and deploying DataStax products and related projects.Ī complete list of current, older, and archived DataStax documentation These findings can assist healthcare providers and decision makers prioritizing targets of secondary prevention and allocation of resources.Īcute myocardial infarction All-cause mortality General population Prognosis.Ĭopyright © 2016. Patients who survived hospital admission with AMI continue to be at higher (approximately twice) risk of death compared with the general population for at least 10-year follow-up period and especially throughout the first and 7th-10th years after AMI, young women, high-risk patients, Jews, NSTEMI, non-invasively treated and recurrent AMI.
Through the follow-up period, SMR was highest during the first year after discharge (SMR, 4.85 P < 0.001) and higher in 7th-10th years compared with 2nd-6th years. Mortality rates increased with age, but SMRs were highest in the youngest group.
Mortality rates and SMRs tended to be greater in higher risk strata of patients, Jews vs Muslims, women vs men, non-ST-elevation acute myocardial infarction (NSTEMI) vs ST-elevation acute myocardial infarction (STEMI), non-invasive treatment vs invasive treatment, and recurrent vs first AMI.
Overall mortality of AMI patients (48.6%) was higher than the general population (SMR, 2.2 P < 0.001). All-cause mortality during the 10-year follow-up period was compared with age-, sex- and ethnicity/religion-matched general population using standardized mortality ratios (SMRs). We evaluated long-term survival after acute myocardial infarction (AMI) in unselected 'real life' patients according to the various risk groups, and it's persistence with time after AMI as compared with the matched general population.ĭata were collected from 2671 AMI hospital survivors (tertiary medical centre in Israel), which included demographics, clinical characteristics of AMI, comorbidities, interventions and test results.